What are SPECT & PET all about?!

Nuclear Medicine Market – Overview

The global market of SPECT offers great prospects and potential. The Nuclear Medicine Diagnostics Market is segmented into two major segments SPECT (Technetium-99m (TC-99m), Iodine (I-123) Thallium-201 (TL-201) and others) and PET (Rubidium-82 (RB-82), Fluorine-18, and others). By application, the market is categorized into SPECT (lymphoma, cardiology, neurology, thyroid and others) and PET (cardiology, oncology, neurology and others).

In the segment of SPECT Technetium 99 holds the major share of the market. It accounts for about 80% of the total market. This majority stake of the market is owing to the fact that Technetium 99 has plentiful uses in the arena of nuclear medicine. Technetium 99 is applied in immunoscintigraphy, SPECT imaging, brain imaging, Cardiac ventriculography,3D scanning techniques and bone scans. Next is Thallium 201 which holds the second majority share in the SPECT segment of the nuclear medicine market and next in line are Iodine 123 and Gallium. The remaining radioisotopes have very few uses when likened to the variety of uses Technetium 99 has. The rudimentary uses of the SPECT market are in the areas of Lymphoma, Cardiology, Neurology, Thyroid, and the other zones of expertise. SPECT has the majority share of applications in the cardiology sector, which involves the scanning, monitoring and imaging of the progress of diagnosis.

PET or Positron Emission Tomography is a technique of imaging used in the field of nuclear medicine that is used to produce a 3D image of the processes of the human body. The PET market is categorized into various segments based on the type of radiopharmaceutical/ radionuclide that has been used. The segmentation includes Fluorine 18 which is referred as FDG 18 and also, Rubidium 82, also referred to as Rb-82 and other radioisotopes with comparatively lesser uses compared to above both. The FDG 18 market offers humungous potential for growth and has positive future prospects. Even though PET is new in the market when compared to SPECT, the growth rate of the PET is higher than that of SPECT, owing to its wider range of applications in the medical industry. The majority of its application confine to the field of oncology, which range from diagnosis, image scanning, and the observing of cancer medications in action. Furthermore, apart from oncology, its applications include Cardiology, Neurology, and Pharmacokinetics.

Among the market segments of PET, the category of FDG 18 has the major market share as compared with the market share of Rubidium, and other radioisotopes. The segment FDG 18 is so vast that it has captured a market share of 16-21 percent of the total nuclear medicine market which includes both PET and SPECT. However, the PET market is anticipated to grow at a higher CAGR for the forthcoming forecast period.  The applications of FDG-PET include the staging, diagnosis, and monitoring treatment of cancers, predominantly in non-Hodgkin lymphoma, Hodgkin’s lymphoma, and also, the cancer of lungs. The applications of PET are under further research and it is expected that the technique will help in the identification of sever malignant and life threatening tumors. In the market segment of PET, FDG accounts for more than 60 percent of all oncology scans in current medical practice.

Furthermore, on the basis of geography, the market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share of the nuclear medicine market, followed by Asia-Pacific and Europe.

Check out Market Data Forecast’s comprehensive reports with in-depth analysis about the Nuclear Medicine Diagnostics Market a free research sample can also be availed. Stay tuned for trending news stories about the latest technologies and interesting Healthcare tit-bits.

Share this post:

Related Posts

Leave a Comment